Vanda Pharmaceuticals Inc

Research Vanda Pharmaceuticals Inc (VNDA) on Bullrun: market cap USD 328.87M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 328.87M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 216.11M-USD 220.50M-USD 110.44M94.0%-3.74USD 84.85MUSD 12.62MUSD 327.19M
FY2024USD 198.77M-USD 18.90M-USD 16.25M94.3%-0.33USD 102.32MUSD 12.36MUSD 538.55M
FY2023USD 192.64MUSD 2.50MUSD 12.42M92.3%0.04USD 135.82MUSD 9.40MUSD 544.91M
FY2022USD 254.38MUSD 6.30MUSD 31.31Mn/a0.11USD 135.03MUSD 11.53MUSD 527.20M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 328.87Mn/an/an/a
20252025-12-31USD 521.28Mn/an/an/a
20242024-12-31USD 279.31Mn/an/an/a
20232023-12-29USD 242.79M20.1n/an/a
20222022-12-30USD 418.20M67.2n/an/a
20212021-12-31USD 877.09M27.1n/an/a

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Vanda Pharmaceuticals Inc's market cap?

Vanda Pharmaceuticals Inc's market capitalization is USD 328.87M.

What does Vanda Pharmaceuticals Inc do?

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.